Masimo (NASDAQ: MASI) today announced the findings of a
prospective study published in the Journal of Orthopaedics in which
Dr. Michael DeRogatis and colleagues at St. Luke’s University
Health Network (SLUHN) in Pennsylvania, joined by researchers at
several additional institutions, evaluated the impact of remote
patient monitoring (RPM) using Masimo SafetyNet® and a hospital’s
virtual response center (VRC) on 30-day readmission rates for
patients undergoing acute postoperative recovery after total joint
arthroplasty (TJA). Masimo SafetyNet, a remote patient management
and telehealth platform, pairs with a variety of Masimo and
third-party devices to seamlessly transmit home-based patient data
to hospital clinicians. The researchers found that patients who
were remotely monitored after being discharged had significantly
lower rates of hospital readmission and ED visits. They concluded,
“Remote home monitoring with a virtual response team after
outpatient TJA is a feasible way to mitigate readmissions in the
acute postoperative period and increase patient satisfaction.”1
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240729113691/en/
Masimo SafetyNet® and MightySat® (Photo:
Business Wire)
Noting that while the trend toward performing TJA as outpatient
surgery reduces hospital length of stay (LOS), the practice
decreases “available time to monitor for postoperative
complications,”1 the authors sought to investigate whether
equipping patients with RPM could offer the best of both worlds:
outpatient surgery with the ability to track vital signs and more
easily stay in touch with patients while they recuperate at home.
They enrolled 100 patients who were scheduled to undergo total knee
or total hip surgery at SLUHN, divided into two groups: 50 who did
not receive RPM after discharge (2021-2022), and 50 who did
(2022-2023). Various characteristics (demographics such as age,
gender, race, BMI, and marital status; hospital LOS; ASA score; and
Charlson Comorbidity Index) were compared between the cohorts and
there were no significant differences (p > 0.05), although
hospital LOS was slightly shorter in the RPM group (29.4 hours vs.
30.4 hours).
Patients in the RPM cohort were discharged with a Masimo
MightySat® pulse oximeter and an Omron blood pressure monitor,
provided by Masimo, which connected wirelessly to the Masimo
SafetyNet app. For 48 hours after discharge, patients checked their
vital signs four times daily. Data recorded by Masimo SafetyNet
(including manually entered temperature data) were automatically
uploaded to the hospital’s virtual response center for review by
hospital clinicians, who reached out to patients as needed to
address abnormalities or signs of physiological decline, provide
guidance, and, if warranted, recommend returning to the facility
for in-person care. Patients in the control group, who did not
receive RPM, were discharged with routine TJA postoperative
instructions.
The researchers found that in the RPM cohort, 10 patients (20%)
recorded abnormal vital signs and 2 patients (4%) visited the ED;
no patients were readmitted to the hospital. In the control cohort,
6 patients (12%) visited the ED and all visits resulted in hospital
admission – significantly higher rates of ED visitation and
hospital readmission (p = 0.03). The causes for the readmissions
included two hip dislocations, cellulitis (soft tissue infection),
and uncontrolled pain. The authors noted that other than the
dislocations, these readmissions “could have been prevented with
remote home monitoring.”1 They conservatively estimated a
readmission cost of $7,000 per patient.
Although they did not conduct a formal cost analysis of the RPM
program, the authors estimated that, after taking into account the
potential cost avoidance of fewer hospital readmissions, for every
1,000 TJA surgeries performed, the RPM program “could potentially
result in a hospital savings of $800,000.”1
The researchers also surveyed patients in the RPM cohort about
their experience and found that most held a favorable view of the
program: 79% strongly or somewhat agreed that RPM helped in their
care at home, 79% strongly or somewhat agreed that it made them
feel safer, and 79% strongly or somewhat agreed they would
recommend RPM to someone they know.
The authors concluded, “As total joint replacements are
increasingly being performed in the outpatient setting,
postoperative patient monitoring from home is a feasible way to
help mitigate readmissions in the postoperative period. The utility
of a virtual response center would be to identify, in real time,
certain patient metrics that could indicate potential complications
and ultimately allow for more timely intervention that may prevent
morbidity and readmissions. Efforts to minimize costs should not be
implemented at the expense of patients’ health outcomes with a goal
to find an appropriate balance between both agendas.”1
Masimo SafetyNet is not intended to be used for real-time
monitoring.
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. In addition, Masimo Consumer Audio is home to eight
legendary audio brands, including Bowers & Wilkins, Denon,
Marantz, and Polk Audio. Our mission is to improve life, improve
patient outcomes, and reduce the cost of care. Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry,
introduced in 1995, has been shown in over 100 independent and
objective studies to outperform other pulse oximetry technologies.2
Masimo SET® has also been shown to help clinicians reduce severe
retinopathy of prematurity in neonates,3 improve CCHD screening in
newborns,4 and, when used for continuous monitoring with Masimo
Patient SafetyNet™ in post-surgical wards, reduce rapid response
team activations, ICU transfers, and costs.5-9 Masimo SET® is
estimated to be used on more than 200 million patients in leading
hospitals and other healthcare settings around the world,10 and is
the primary pulse oximetry at all 10 top U.S. hospitals as ranked
in the 2024 Newsweek World’s Best Hospitals listing.11 In 2005,
Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total
hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin
(SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®),
RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013,
Masimo introduced the Root® Patient Monitoring and Connectivity
Platform, built from the ground up to be as flexible and expandable
as possible to facilitate the addition of other Masimo and
third-party monitoring technologies; key Masimo additions include
Next Generation SedLine® Brain Function Monitoring, O3® Regional
Oximetry, and ISA™ Capnography with NomoLine® sampling lines.
Masimo’s family of continuous and spot-check monitoring Pulse
CO-Oximeters® includes devices designed for use in a variety of
clinical and non-clinical scenarios, including tetherless, wearable
technology, such as Radius-7®, Radius PPG®, and Radius VSM™,
portable devices like Rad-67®, fingertip pulse oximeters like
MightySat® Rx, and devices available for use both in the hospital
and at home, such as Rad-97® and the Masimo W1® Medical Watch.
Masimo hospital and home automation and connectivity solutions are
centered around the Masimo Hospital Automation™ platform, and
include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo
ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing
portfolio of health and wellness solutions includes Radius Tº® and
Masimo W1 Sport. Additional information about Masimo and its
products may be found at www.masimo.com. Published clinical studies
on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
RPVi has not received FDA 510(k) clearance and is not available
for sale in the United States. The use of the trademark Patient
SafetyNet is under license from University HealthSystem
Consortium.
References
- DeRogatis MJ, Pellegrino AN, Wang N, Higgins M, Dubin J, Issack
P, Sokunbi G, Brogle P, Konopitski A. Enhancing recovery and
reducing readmissions: The impact of remote monitoring on acute
postoperative care in outpatient total joint arthroplasty. J Ortho.
26 June 2024. 58(2024). DOI: 10.1016/j.jor.2024.60.028.
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar. DOI: 10.1097/PTS.0000000000000696.
- Estimate: Masimo data on file.
-
https://www.newsweek.com/rankings/worlds-best-hospitals-2024/united-states
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo SafetyNet® and
MightySat®. These forward-looking statements are based on current
expectations about future events affecting us and are subject to
risks and uncertainties, all of which are difficult to predict and
many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in
our forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies, including Masimo SafetyNet and MightySat, contribute
to positive clinical outcomes and patient safety; risks related to
our belief that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; risks that the
researchers’ conclusions and findings may be inaccurate; risks
related to COVID-19; as well as other factors discussed in the
"Risk Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be obtained
for free at the SEC's website at www.sec.gov. Although we believe
that the expectations reflected in our forward-looking statements
are reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these statements or the "Risk Factors" contained
in our most recent reports filed with the SEC, whether as a result
of new information, future events or otherwise, except as may be
required under the applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240729113691/en/
Media Contact: Masimo Evan Lamb 949-396-3376
elamb@masimo.com
Masimo (NASDAQ:MASI)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Masimo (NASDAQ:MASI)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024